|
|
||||||||



*
Laboratory of Immunology, Istituto Dermopatico dellImmacolata, IRCCS, Rome, Italy; and
Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
| Abstract |
|---|
|
|
|---|
, and undetectable IL-4. These cells
inhibit in a IL-10-dependent manner the capacity of dendritic cells to
activate nickel-specific Tc1 and Th1 lymphocytes. RNase protection
assay and FACS analysis revealed the expression of a vast repertoire of
chemokine receptors on resting ThIL-10, including the
Th1-associated CXCR3 and CCR5, and the Th2-associated CCR3, CCR4, and
CCR8, the latter at higher levels compared with Th2 cells. The most
active chemokines for resting ThIL-10, in terms of calcium
mobilization and in vitro migration, were in order of potency: CCL2
(monocyte chemoattractant protein-1, CCR2 ligand), CCL4
(macrophage-inflammatory protein-1
, CCR5 ligand), CCL3
(macrophage-inflammatory protein-1
, CCR1/5 ligand), CCL17 (thymus
and activation-regulated chemokine, CCR4 ligand), CCL1 (I-309, CCR8
ligand), CXCL12 (stromal-derived factor-1, CXCR4), and CCL11 (eotaxin,
CCR3 ligand). Consistent with receptor expression down-regulation,
activated ThIL-10 exhibited a reduced or absent response to
most chemokines, but retained a significant migratory capacity to
I-309, monocyte chemoattractant protein-1, and thymus and
activation-regulated chemokine. I-309, which was ineffective on Th1
lymphocytes, attracted more efficiently ThIL-10 than Th2
cells. I-309 and CCR8 mRNAs were not detected in unaffected skin and
were up-regulated at the skin site of nickel-allergic reaction, with an
earlier expression kinetics compared with IL-10 and IL-4. Results
indicate that skin-homing regulatory ThIL-10 lymphocytes
coexpress functional Th1- and Th2-associated chemokine receptors, and
that CCR8/I-309-driven recruitment of both resting and activated
ThIL-10 cells may be critically involved in the regulation
of Th1-mediated skin allergic disorders. | Introduction |
|---|
|
|
|---|
, and no IL-4
(11). These nickel-specific IL-10-producing Th cells
(ThIL-10)3
express the skin-homing receptor, cutaneous lymphocyte-associated Ag
(CLA), and block in a IL-10-dependent manner the differentiation and
maturation of dendritic cells, thus impairing their capacity to
activate nickel-specific Tc1 and Th1 effector lymphocytes
(12). Many recent findings indicate that chemokine receptors are differentially expressed on memory T cells depending on their polarization (13, 14, 15, 16, 17, 18), with Th1 lymphocytes expressing CCR5 and CXCR3, and Th2 lymphocytes CCR3, CCR4, and CCR8. As a consequence, selective chemotactic stimuli contribute to the differential positioning of Th1 and Th2 cells within tissues (19, 20, 21). Here, we analyzed the chemokine receptor profile and migratory properties of skin-homing nickel-specific ThIL-10 lymphocytes. Our results demonstrate that resting ThIL-10 cells coexpress functional Th1 and Th2 chemokine receptors and migrate in response to a variety of chemokines. Upon activation, ThIL-10 cells are attracted exclusively by CCL1 (I-309), CCL2 (monocyte chemoattractant protein-1, MCP-1), CCL17 (thymus and activation-regulated chemokine, TARC), and CXCL12 (stromal derived factor 1, SDF-1). I-309, which is produced in the skin affected with allergic contact dermatitis to nickel, attracts ThIL-10 and Th2, but not Th1 cells, and may thus contribute to the regulation of the Th1-mediated skin inflammation.
| Materials and Methods |
|---|
|
|
|---|
T lymphocytes were cultured in RPMI 1640 supplemented with 2 mM glutamine, 1 mM sodium pyruvate, 1% nonessential amino acids, 0.05 mM 2-ME, 100 U/ml penicillin, and 100 µg/ml streptomycin (all from Life Technologies, Chagrin Falls, OH) (complete RPMI) plus 10% heat-inactivated FCS (HyClone Logan, UT) or 5% autologous plasma. The anti-CD28 mAb (Leu-28, IgG1) was purchased from Becton Dickinson (San Jose, Ca). Mouse mAbs anti-human CCR1 (53504.111, IgG2B), CCR2 (48607.121, IgG2B), CCR5 (45531.111, IgG2B), and CXCR3 (49801.111, IgG1) were obtained from R&D Systems (Minneapolis, MN); anti-CCR3 (LS63 7B11, IgG2A) and anti-CCR4 (328B, IgG) mAbs were kindly provided by Leukosite (Cambridge, MA) and ICOS (Bothell, WA), respectively; anti-CXCR1 (5A12, IgG2B), CXCR2 (6C6, IgG1) and CXCR4 (12G5, IgG2A) were purchased from PharMingen (San Diego, CA). Anti-CD3 (UCHT-1, IgG1) was obtained from Immunotech (Marseille, France); the FITC-conjugated anti-CLA mAb (HECA-452, rat IgM), the control isotype FITC-conjugated rat IgM, and the control mouse IgG were purchased from PharMingen. FITC-conjugated goat anti-mouse IgG were obtained from Dako (Glostrup, Denmark).
T cell clones
T cell lines were derived from the blood and skin of nonatopic
patients affected by allergic contact dermatitis to nickel, as
previously described (12). Briefly, >95% pure
CD4+ T cells were negatively selected from the
nonadherent fraction of PBMC using immunomagnetic beads coated with
anti-CD19, anti-HLA-DR, and anti-CD8 mAbs (Dynal, Oslo,
Norway). Blood-derived CD4+ T cells were expanded
with autologous PBMC and 10 µg/ml NiSO4
(Sigma-Aldrich, Milan, Italy) to enrich for nickel-specific T cells.
Skin-derived T cells were obtained from 4-mm punch biopsies performed
48 h after the application of 5% NiSO4 in
petrolatum on the back of allergic patients. After extensive washing in
PBS, biopsies were placed in culture at 37°C with 5%
CO2 in complete RPMI along with 5% autologous
plasma and 30 U/ml rhIL-2 (generously provided by Chiron Italia, Milan,
Italy). Medium was replaced every third day, and T cells emigrating
from the tissue were collected at day 10. Blood- and skin-derived T
cell lines were cloned by limiting dilution (0.5 cells/well) in the
presence of 2 x 105 PBMC, 30 U/ml IL-2, and
1% PHA in complete RPMI plus 10% FCS. Clones were grown in the
presence of IL-2 and periodically stimulated with 1% PHA and feeder
cells or plate-coated anti-CD3 (1 µg/ml) and soluble
anti-CD28 (1 µg/ml) mAbs. Ag specificity of T cell lines and
clones was tested using irradiated PBMC and 10 µg/ml
NiSO4 in complete RPMI supplemented with 5%
autologous plasma for 48 h and pulsed with 5 µCi/ml
[3H]TdR (Amersham, Little Chalfont, U.K.) for
the last 12 h of culture. Cultures were harvested onto
fiber-coated 96-well plates, and thymidine incorporation was measured
in a beta counter (Topcount; Packard, Groningen, The Netherlands).
Supernatants from T cells (106 cells/ml)
stimulated in 24-well plates with immobilized anti-CD3 and soluble
anti-CD28 mAbs were collected after 48 h, filtered, and tested
for IL-10, IL-4, IFN-
, and TGF-
content by ELISA (R&D
Systems).
RNase protection assay
Total RNA was extracted from resting and 6-to 48-h activated T cell clones using TRIzol (Life Technologies) according to the manufacturers instructions. Two multiprobe template sets, hCR5 and hCR6 (RiboQuant; PharMingen), were used for in vitro transcription reactions in the presence of a GACU pool and a T7 RNA polymerase to synthesize [32P]UTP-labeled antisense probes. RNase protection analysis of 2.5 µg of total RNA was performed after overnight hybridization at 60°C with 2.5 x 106 cpm of hCR5 or hCR6, followed by digestion with RNase A and T1 according to standard protocols. Protected fragments were treated with proteinase K, extracted with phenol-chloroform plus isoamyl alcohol (50:1), and finally precipitated in ethanol in the presence of ammonium acetate. The samples were electrophoresed on 5% denaturing sequencing gels and then exposed on film (Kodak, Rochester, NY). The levels of mRNA expression were quantified by densitometric analysis with an imaging densitometer (model GS-670; Bio-Rad, Hercules, CA), supported by the Molecular Analyst Image software, and the values were normalized against the housekeeping gene L32.
FACS analysis
ThIL-10 lymphocytes in resting condition or activated 48 h with immobilized anti-CD3 were washed in PBS added with 1% FBS and stained with specific mAb or isotype control Ig, followed by secondary anti-mouse FITC-conjugated Ab. For CCR1 detection, cells were preincubated for 15 min with 2% paraformaldehyde and then permeabilized with 0.5% saponin for 20 min before staining with the mAb or the isotype control. Cells were analyzed with a FACScan equipped with CellQuest software (Becton Dickinson).
Intracellular Ca2+ concentration measurements
T cell clones were either left untreated or activated with
anti-CD3 plus anti-CD28 for 48 h in the presence of 30
U/ml IL-2. Thereafter, cells (5 x 106/ml)
were washed and loaded with 8 µM Fluo-3/acetoxymethyl ester in the
presence of 1 µM pluronic F-127 (Molecular Probes, Eugene, OR) in
complete RPMI with 1% FBS for 40 min at 37°C with frequent gentle
agitation. Cells were then washed twice, stimulated with CCL3
(macrophage inflammatory protein (MIP)-1
, 200 ng/ml), MCP-1 (200
ng/ml), CCL11 (eotaxin, 400 ng/ml), TARC (100 ng/ml), CCL4 (MIP-1
,
100 ng/ml), CCL19 (MIP-3
, 30 ng/ml), I-309 (200 ng/ml), CXCL8 (IL-8,
100 ng/ml), CXCL10 (IFN-induced protein of 10 kDa (IP-10), 100 ng/ml),
and SDF-1 (100 ng/ml) (all from R&D Systems), and finally analyzed on a
FACScan. Cells and chemokines were maintained at 37°C during the
assay.
Migration assay
Chemotactic property of each chemokine was evaluated measuring the lymphocyte migration through a 5-µm pore polycarbonate filter in 24-well transwell chambers (Corning Costar, Cambridge MA) as previously described (22). Briefly Th1, Th2, and ThIL-10 either in resting or stimulated 48 h with immobilized anti-CD3 plus anti-CD28 were added to the top chamber suspended in complete RPMI plus 0.5% BSA at 1 x 106 cells/ml. Various concentrations of the different chemokines were added to the bottom chamber of the transwell (0.6 ml). After 1 h of incubation at 37°C with 5% CO2, cells transmigrated into the lower chamber were recovered and counted with a FACScan for 60 s at a flow rate of 60 µl/min, as previously described (23). Results are shown as migration index, which represents the ratio between T cells migrated to the lower chamber in the presence of the agonistic chemokine and cells migrated in response to the medium alone.
RT-PCR analysis
Total cellular RNA was extracted from 4-mm punch skin biopsies
obtained at time 0 and 16, 48 and 60 h after the application of
5% NiSO4 on the back of allergic individuals
(n = 2) using the acid guanidinium
thiocyanate-phenol-chloroform method. Total RNA (0.51 µg) was
reverse transcribed using oligo(dT) primers and then subjected to
amplification with a GeneAmp RNA PCR kit (Perkin-Elmer, Roche Molecular
Systems, Branchburg, NJ). The following synthetic oligonucleotides were
used: for I-309, 5'-ATG CAG ATC ATC ACC ACA GCC CTG and 3'-ACA GAA AAA
TGC TGA GGC ACT GCC (274-bp amplificate); for CCR8, 5'-CAT CAC CCT CAT
GAG TGT GG and 3'-CAC GTT GAA TGG GAC CCA GA (410-bp amplificate); for
IL-10, 5'-GAA GGA TCA GCT GGA CAA CTT GTT G and 3'-GCT CCA AAT GTA GGG
GCA GG (306-bp amplificate); for IL-4, 5'-GCG ATA TCA CCT TAC AGG AG
and 3'-TTG GCT TCC TTC ACA GGA CA (308-bp amplificate); for IFN-
,
5'-TGC AGG TCA TTC AGA TGT AG and 3'-AGC CAT CAC TTG GAT GAG TT (306-bp
amplificate) (24). The
-actin housekeeping gene was
amplified with 5'-TGA CGG GGT CAC CCA CAC TGT GCC CAT CTA and 3'-CTA
GAA GCA TTT GCG GTG GAC GAT GGA GGG primers (660-bp amplificate). To
eliminate genomic DNA contamination, reverse transcription was
performed after digestion with RNase-free DNase (PharMingen) for 30 min
at 37°C. As a control, reactions were also performed in the absence
of reverse transcriptase. For semiquantitative analysis, RNA
concentrations, primers, and PCR cycles were titrated to obtain
standard curves to verify linearity and to permit analysis of signal
strength. The levels of mRNA expression were quantified by
densitometric analysis as described above, with the values normalized
against
-actin.
| Results |
|---|
|
|
|---|
T cell clones were isolated from either the peripheral blood or
lesional skin of patients affected with allergic contact dermatitis to
nickel. ThIL-10 clones released high amounts of
IL-10, low levels of IFN-
, and very limited amounts or no IL-4, and
expressed the CLA receptor which allows the recruitment of memory T
cells in the skin (8) (Table I
). To determine the chemokine receptor
expression, T cell clones were collected in resting phase and 648 h
after anti-CD3/anti-CD28-induced activation, and the mRNA
content was evaluated by RNase protection assay using CC and CXC
chemokine receptor multiprobe template sets. In resting conditions,
ThIL-10 cells expressed a wide range of CC and
CXC receptors (Figs. 1
and 2
). As previously reported for other T
cell subsets (25), TCR engagement strongly affected
chemokine receptor expression. After a transient burst at 6 h in
CCR1, CCR2, CCR4, CCR5, and CCR8 mRNA, ThIL-10
clones down-regulated CXC (CXCR1, CXCR3, and CXCR4) receptors, CCR2,
and, to a lesser extent, CCR3 and CCR8. In contrast, CCR1, CCR4, CCR5,
and CCR7 were up-regulated. When compared with Th1 and Th2,
ThIL-10 lymphocytes displayed a broader array of
chemokine receptors, with significant expression of both the
Th1-associated CCR5 and CXCR3 and the Th2-associated CCR3, CCR4, and
CCR8 (13, 14, 15, 16, 17, 18, 25). Interestingly, the mRNA signal for CCR8
was 2-fold stronger in resting ThIL-10
lymphocytes than in Th2 clones, and the difference was even more
pronounced upon activation, being CCR8 markedly down-regulated in
TCR-engaged Th2 lymphocytes, but only slightly in
ThIL-10 cells. ThIL-10, but
not Th1 and Th2, clones expressed low levels of CCR7 mRNA, which was
up-regulated upon activation. Finally, both resting and stimulated
ThIL-10 clones showed 1.5- to 3.5-fold higher
CXCR4 mRNA levels than Th1 and Th2 cells.
|
|
|
FACS analysis confirmed the expression of the CCRs 15 and the
CXCRs 1, 3, and 4 on resting ThIL-10 lymphocytes,
whereas CXCR2 was negative (Fig. 3
).
Activated ThIL-10 lymphocytes strongly reduced
the surface expression of CCR1, CCR3, CCR5, CXCR1, and CXCR3. Although
CCR1 and CCR5 protein expression decreased, the corresponding mRNA
signals were up-regulated following TCR triggering. The expression of
CCR2 and CCR4, albeit reduced, was maintained at significant levels and
that of CXCR4 was unmodified after ThIL-10
activation.
|
To evaluate the functional relevance of chemokine receptor
expression, we measured calcium mobilization in
ThIL-10 lymphocytes after treatment with
agonistic chemokines. Consistent with the vast repertoire of receptors
expressed, all of the chemokines tested induced significant responses
in resting ThIL-10 cells (Fig. 4
). The most
active chemokines were MCP-1 (CCR2 ligand), I-309 (CCR8 ligand),
MIP-1
(CCR1CCR5 ligand), and MIP-1
(CCR5 ligand), followed by
TARC (CCR4 ligand), IL-8 (CXCR1 ligand) and eotaxin (CCR3 ligand),
SDF-1 (CXCR4 ligand), and finally MIP-3
(CCR7 ligand). After
activation, significant calcium fluxes were measured in response to
I-309, MCP-1, TARC, and SDF-1, whereas the responses to the other
chemokines were strongly reduced or completely lost. Consistent with
the up-regulation of CCR7 mRNA, MIP-3
retained a slight stimulatory
effect on activated ThIL-10 clones. Notably,
activated ThIL-10 cells became unresponsive to
MIP-1
and MIP-1
, in line with the decreased expression of CCR1
and CCR5 receptors. This finding has been previously observed in mature
dendritic cells and activated monocytes (26, 27).
|
The migratory behavior of Th1, Th2, and
ThIL-10 lymphocytes was compared by measuring
their transmigration through transwell filters in response to different
concentrations of agonistic chemokines (Fig. 5
). Resting ThIL-10
revealed an extraordinary capacity to migrate in response to a broad
array of chemotactic stimuli, including both Th1- and Th2-associated
chemokines. The highest migration was achieved with MCP-1, MIP-1
,
and MIP-1
, followed by TARC, I-309, SDF-1, and eotaxin, whereas more
limited responses were observed to IL-8, IP-10, and MIP-3
.
ThIL-10 migration to MIP-1
, IP-10 (CCR5 and
CXCR3 ligands), and to eotaxin (CCR3 ligand) was lower compared with
that of Th1 and Th2 clones, respectively. In contrast, I-309 induced a
stronger migration in ThIL-10 than in Th2 cells.
Responses to MIP-1
, MCP-1, and TARC were comparable among the
different Th cell subsets, whereas ThIL-10 and
Th2 migrated to a higher extent in response to IL-8 compared with Th1
clones. IL-8 responsiveness was likely due to CXCR1, but not CXCR2
triggering, since the latter receptor was undetectable on
ThIL-10 both at mRNA and protein levels.
Additionally, neutrophil-activating protein-2, a specific agonist of
CXCR2 but not CXCR1, failed to induce calcium mobilization and
migration of ThIL-10 (data not shown). Finally,
only ThIL-10 cells showed a slight migration to
MIP-3
. After stimulation with anti-CD3 and anti-CD28 mAbs,
ThIL-10 cells markedly decreased their migratory response
to most of the chemokines, and, consistent with the calcium fluxes,
retained a significant migration to MCP-1, I-309, TARC, and SDF-1.
MCP-1 and TARC were also effective in attracting activated Th1 and Th2
lymphocytes, whereas I-309 attracted Th2, but not Th1 cells. Activated
Th1 lymphocytes maintained a significant response to MIP-1
,
MIP-1
, and IP-10.
|
Since I-309 appeared to selectively attract
ThIL-10 and Th2 lymphocytes and was effective on
both resting and activated ThIL-10 cells, its
expression was investigated during allergic contact dermatitis
reaction, in combination with CCR8, IL-10, IL-4, and IFN-
. RT-PCR
was performed on RNA extracted from unaffected (time 0) skin and at 16,
48, and 60 h after nickel challenge. Fig. 6
demonstrates that I-309, CCR8, IL-10, and IL-4 mRNAs were undetectable
in normal skin. Both CCR8 and I-309 were already expressed at 16 h
after nickel application and reached a peak at 48 h, whereas IL-4
and IL-10 mRNAs became detectable only after 48 h. In contrast, a
faint signal for IFN-
mRNA was already present in unaffected skin,
augmented at 1648 h, and decreased thereafter.
|
| Discussion |
|---|
|
|
|---|
was similar
in all subsets. In contrast, resting ThIL-10
cells showed a lower response to MIP-1
and IP-10 compared with Th1,
and to eotaxin compared with Th2 clones. Noteworthy, CCR8, considered a
very specific Th2 marker (17, 18), was highly expressed in
ThIL-10 cells, with I-309 attracting more
efficiently ThIL-10 than Th2 cells. TCR-engaged
ThIL-10 lymphocytes down-regulated most chemokine
receptors, both at the mRNA and protein levels. As a consequence,
activated ThIL-10 became unresponsive to many
chemotactic stimuli, still maintaining a significant response to I-309,
MCP-1, TARC, and SDF-1. Interestingly, although CCR1 and CCR5 mRNA were
up-regulated, FACS analysis revealed a strong down-regulation of the
receptors in activated ThIL-10, which became
unresponsive to MIP-1
and MIP-1
. This finding may indicate a
posttranscriptional regulation, as suggested to occur for CCR5 in
activated dendritic cells and monocytes (26, 27). CCR4,
which has been associated with Th2 polarization (15, 16, 18), was expressed by all of the skin-homing T cell subsets,
although at higher levels in resting Th2 cells compared with Th1 and
ThIL-10 lymphocytes (10- and 2-fold higher,
respectively). This finding is consistent with the recent report by
Campbell et al. (28), indicating that CCR4 is involved in
the skin homing of memory T lymphocytes, being coexpressed on the
majority of CLA+ T cells independently of the
cytokine profile.
IL-10-releasing T lymphocytes with regulatory function have been
obtained in vivo after repeated intranasal stimulation with peptide Ag
(29) or repeated superantigen challenge (30),
and following immunization through UVB-irradiated skin
(31). In addition, Groux et al. (32) have
shown that murine and human lymphocytes cultured in the presence of
IL-10 develop a phenotype characterized by high release of IL-10, IL-5,
and TGF-
, variable amounts of IFN-
, and no IL-4. These
lymphocytes, called T regulatory cells 1 (Tr1), inhibit immune
responses both in vitro and in vivo in a IL-10-dependent manner. More
recently, a Tr1 polarization was induced in vitro by using dendritic
cells treated with corticosteroids (33). Our skin-homing
ThIL-10 cells resemble Tr1 lymphocytes, but
release lower levels of IFN-
and display variable TGF-
production. Moreover, nickel-specific ThIL-10
lymphocytes display the IL-12R
2 chain, the CD26 and the lymphocyte
activation Ag-3 (12), markers related to a Th1
polarization. Whether these suppressive ThIL-10
cells represent a distinct Th subset or a further maturation step of
Th1 or Th2 cells has to be determined.
An interesting observation of our study was that I-309 was capable of
attracting more efficiently ThIL-10 than Th2
cells, both in resting and activated conditions, whereas it was
ineffective on Th1. We also found that I-309 mRNA was significantly
expressed in the skin after Ag challenge. I-309 expression paralleled
that of CCR8 and preceded IL-4 and IL-10 expression. I-309-mediated
recruitment of ThIL-10 cells may thus represent
an important mechanism for terminating Th1-mediated allergic reactions
and limiting excessive tissue damage. In line with this hypothesis, it
has been shown that administration of IL-10 strongly reduces murine
contact hypersensitivity (34, 35), and IL-10-deficient
mice show enhanced and more sustained cutaneous inflammatory responses
to haptens (36). Activated Th1 and Th2 lymphocytes are the
major source of I-309 (25, 37), but we have recently found
a significant production of I-309 by IFN-
-stimulated keratinocytes
(C. Albanesi, C. Scarponi, S. Sebastiani, A. Cavani, M. Federici, S.
Sozzani, and G. Girolomoni, manuscript in preparation), which may
therefore contribute relevantly to the recruitment of regulatory
ThIL-10 cells in the skin. In aggregate, our
results demonstrate that ThIL-10 display a broad
array of functional chemokine receptors, which allow their comigration
along with Th1 and Th2 cells. The expression of high levels of CCR8 in
regulatory ThIL-10 lymphocytes may be
advantageously exploited to control Th1-mediated allergic
disorders.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Andrea Cavani, Laboratory of Immunology, Istituto Dermopatico dellImmacolata, IRCCS Via Monti di Creta 104, I-00167 Rome, Italy. ![]()
3 Abbreviations used in this paper: ThIL-10, IL-10-producing Th cells; CLA, cutaneous lymphocyte-associated Ag; MCP, monocyte chemoattractant protein; TARC, thymus and activation-regulated chemokine; SDF, stromal-derived factor; MIP, macrophage-inflammatory protein; IP-10, IFN-induced protein of 10 kDa; Tr1, T regulatory cell 1. ![]()
Received for publication July 27, 2000. Accepted for publication October 30, 2000.
| References |
|---|
|
|
|---|
6
1 and chemokine receptor CCR1 by interleukin-12 promotes the migration of human type 1 helper T cells. Blood 94:2981.This article has been cited by other articles:
![]() |
M. E. Moreno-Fernandez, W. Zapata, J. T. Blackard, G. Franchini, and C. A. Chougnet Human Regulatory T Cells Are Targets for Human Immunodeficiency Virus (HIV) Infection, and Their Susceptibility Differs Depending on the HIV Type 1 Strain J. Virol., December 15, 2009; 83(24): 12925 - 12933. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Yessoufou, A. Ple, K. Moutairou, A. Hichami, and N. A. Khan Docosahexaenoic acid reduces suppressive and migratory functions of CD4CD25 regulatory T-cells J. Lipid Res., December 1, 2009; 50(12): 2377 - 2388. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kimpfler, A. Sevko, S. Ring, C. Falk, W. Osen, K. Frank, M. Kato, K. Mahnke, D. Schadendorf, and V. Umansky Skin Melanoma Development in ret Transgenic Mice Despite the Depletion of CD25+Foxp3+ Regulatory T Cells in Lymphoid Organs J. Immunol., November 15, 2009; 183(10): 6330 - 6337. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Picchio, E. Scala, D. Pomponi, E. Caprini, M. Frontani, I. Angelucci, A. Mangoni, C. Lazzeri, M. Perez, D. Remotti, et al. CXCL13 Is Highly Produced by Sezary Cells and Enhances Their Migratory Ability via a Synergistic Mechanism Involving CCL19 and CCL21 Chemokines Cancer Res., September 1, 2008; 68(17): 7137 - 7146. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Mira, B. Leon, D. F. Barber, S. Jimenez-Baranda, I. Goya, L. Almonacid, G. Marquez, A. Zaballos, C. Martinez-A., J. V. Stein, et al. Statins Induce Regulatory T Cell Recruitment via a CCL1 Dependent Pathway J. Immunol., September 1, 2008; 181(5): 3524 - 3534. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Baatar, P. Olkhanud, D. Newton, K. Sumitomo, and A. Biragyn CCR4-Expressing T Cell Tumors Can Be Specifically Controlled via Delivery of Toxins to Chemokine Receptors J. Immunol., August 1, 2007; 179(3): 1996 - 2004. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Baatar, P. Olkhanud, K. Sumitomo, D. Taub, R. Gress, and A. Biragyn Human Peripheral Blood T Regulatory Cells (Tregs), Functionally Primed CCR4+ Tregs and Unprimed CCR4- Tregs, Regulate Effector T Cells Using FasL J. Immunol., April 15, 2007; 178(8): 4891 - 4900. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kallikourdis, K. G. Andersen, K. A. Welch, and A. G. Betz Alloantigen-enhanced accumulation of CCR5+ 'effector' regulatory T cells in the gravid uterus PNAS, January 9, 2007; 104(2): 594 - 599. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-H. Zarnani, S.-M. Moazzeni, F. Shokri, M. Salehnia, and M. Jeddi-Tehrani Kinetics of murine decidual dendritic cells Reproduction, January 1, 2007; 133(1): 275 - 283. [Abstract] [Full Text] [PDF] |
||||
![]() |
C Lopez, M Comabella, M Tintore, J Sastre-Garriga, and X Montalban Variations in chemokine receptor and cytokine expression during pregnancy in multiple sclerosis patients Multiple Sclerosis, August 1, 2006; 12(4): 421 - 427. [Abstract] [PDF] |
||||
![]() |
M. Sironi, F. O. Martinez, D. D'Ambrosio, M. Gattorno, N. Polentarutti, M. Locati, A. Gregorio, A. Iellem, M. A. Cassatella, J. Van Damme, et al. Differential regulation of chemokine production by Fc{gamma} receptor engagement in human monocytes: association of CCL1 with a distinct form of M2 monocyte activation (M2b, Type 2) J. Leukoc. Biol., August 1, 2006; 80(2): 342 - 349. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Narducci, E. Scala, A. Bresin, E. Caprini, M. C. Picchio, D. Remotti, G. Ragone, F. Nasorri, M. Frontani, D. Arcelli, et al. Skin homing of Sezary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26/dipeptidylpeptidase IV Blood, February 1, 2006; 107(3): 1108 - 1115. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Bendriss-Vermare, S. Burg, H. Kanzler, L. Chaperot, T. Duhen, O. de Bouteiller, M. D'agostini, J.-M. Bridon, I. Durand, J. M. Sederstrom, et al. Virus overrides the propensity of human CD40L-activated plasmacytoid dendritic cells to produce Th2 mediators through synergistic induction of IFN-{gamma} and Th1 chemokine production J. Leukoc. Biol., October 1, 2005; 78(4): 954 - 966. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. R. Veillard, S. Steffens, G. Pelli, B. Lu, B. R. Kwak, C. Gerard, I. F. Charo, and F. Mach Differential Influence of Chemokine Receptors CCR2 and CXCR3 in Development of Atherosclerosis In Vivo Circulation, August 9, 2005; 112(6): 870 - 878. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Freeman, B.-C. Chiu, V. R. Stolberg, J. Hu, K. Zeibecoglou, N. W. Lukacs, S. A. Lira, S. L. Kunkel, and S. W. Chensue CCR8 Is Expressed by Antigen-Elicited, IL-10-Producing CD4+CD25+ T Cells, Which Regulate Th2-Mediated Granuloma Formation in Mice J. Immunol., February 15, 2005; 174(4): 1962 - 1970. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. R. Veillard, S. Steffens, F. Burger, G. Pelli, and F. Mach Differential Expression Patterns of Proinflammatory and Antiinflammatory Mediators During Atherogenesis in Mice Arterioscler Thromb Vasc Biol, December 1, 2004; 24(12): 2339 - 2344. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kipnis, M. Cardon, H. Avidan, G. M. Lewitus, S. Mordechay, A. Rolls, Y. Shani, and M. Schwartz Dopamine, through the Extracellular Signal-Regulated Kinase Pathway, Downregulates CD4+CD25+ Regulatory T-Cell Activity: Implications for Neurodegeneration J. Neurosci., July 7, 2004; 24(27): 6133 - 6143. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Schaerli, L. Ebert, K. Willimann, A. Blaser, R. S. Roos, P. Loetscher, and B. Moser A Skin-selective Homing Mechanism for Human Immune Surveillance T Cells J. Exp. Med., May 3, 2004; 199(9): 1265 - 1275. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Cavani, F. Nasorri, C. Ottaviani, S. Sebastiani, O. De Pita, and G. Girolomoni Human CD25+ Regulatory T Cells Maintain Immune Tolerance to Nickel in Healthy, Nonallergic Individuals J. Immunol., December 1, 2003; 171(11): 5760 - 5768. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mitola, M. Strasly, M. Prato, P. Ghia, and F. Bussolino IL-12 Regulates an Endothelial Cell-Lymphocyte Network: Effect on Metalloproteinase-9 Production J. Immunol., October 1, 2003; 171(7): 3725 - 3733. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kao, J. Kobashigawa, M. C. Fishbein, W. R. MacLellan, M. D. Burdick, J. A. Belperio, and R. M. Strieter Elevated Serum Levels of the CXCR3 Chemokine ITAC Are Associated With the Development of Transplant Coronary Artery Disease Circulation, April 22, 2003; 107(15): 1958 - 1961. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Y. Savinov, F. S. Wong, A. C. Stonebraker, and A. V. Chervonsky Presentation of Antigen by Endothelial Cells and Chemoattraction Are Required for Homing of Insulin-specific CD8+ T Cells J. Exp. Med., March 3, 2003; 197(5): 643 - 656. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Mo, J. Chen, Y. Han, C. Bueno-Cannizares, D. E. Misek, P. A. Lescure, S. Hanash, and R. L. Yung T Cell Chemokine Receptor Expression in Aging J. Immunol., January 15, 2003; 170(2): 895 - 904. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. D. Chung, F. Kuo, J. Kumer, A. S. Motani, C. E. Lawrence, W. R. Henderson Jr., and C. Venkataraman CCR8 Is Not Essential for the Development of Inflammation in a Mouse Model of Allergic Airway Disease J. Immunol., January 1, 2003; 170(1): 581 - 587. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Penna, M. Vulcano, A. Roncari, F. Facchetti, S. Sozzani, and L. Adorini Cutting Edge: Differential Chemokine Production by Myeloid and Plasmacytoid Dendritic Cells J. Immunol., December 15, 2002; 169(12): 6673 - 6676. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Nakajima, N. Inagaki, H. Tanaka, A. Tanaka, M. Yoshikawa, M. Tamari, K. Hasegawa, K. Matsumoto, H. Tachimoto, M. Ebisawa, et al. Marked increase in CC chemokine gene expression in both human and mouse mast cell transcriptomes following Fcepsilon receptor I cross-linking: an interspecies comparison Blood, December 1, 2002; 100(12): 3861 - 3868. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Stephens, D. A. Randolph, G. Huang, M. J. Holtzman, and D. D. Chaplin Antigen-Nonspecific Recruitment of Th2 Cells to the Lung as a Mechanism for Viral Infection-Induced Allergic Asthma J. Immunol., November 15, 2002; 169(10): 5458 - 5467. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Stephens and D. D. Chaplin IgE Cross-Linking or Lipopolysaccharide Treatment Induces Recruitment of Th2 Cells to the Lung in the Absence of Specific Antigen J. Immunol., November 15, 2002; 169(10): 5468 - 5476. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Akiba, J. Kehren, M.-T. Ducluzeau, M. Krasteva, F. Horand, D. Kaiserlian, F. Kaneko, and J.-F. Nicolas Skin Inflammation During Contact Hypersensitivity Is Mediated by Early Recruitment of CD8+ T Cytotoxic 1 Cells Inducing Keratinocyte Apoptosis J. Immunol., March 15, 2002; 168(6): 3079 - 3087. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. K. Maxion and K. A. Kelly Chemokine Expression Patterns Differ within Anatomically Distinct Regions of the Genital Tract during Chlamydia trachomatis Infection Infect. Immun., March 1, 2002; 70(3): 1538 - 1546. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. McGuirk, C. McCann, and K. H.G. Mills Pathogen-specific T Regulatory 1 Cells Induced in the Respiratory Tract by a Bacterial Molecule that Stimulates Interleukin 10 Production by Dendritic Cells: A Novel Strategy for Evasion of Protective T Helper Type 1 Responses by Bordetella pertussis J. Exp. Med., January 22, 2002; 195(2): 221 - 231. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Artik, K. Haarhuis, X. Wu, J. Begerow, and E. Gleichmann Tolerance to Nickel: Oral Nickel Administration Induces a High Frequency of Anergic T Cells with Persistent Suppressor Activity J. Immunol., December 15, 2001; 167(12): 6794 - 6803. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |